well supported · human dataDiscovery of the day
Pooled results from seven trials in 821 people with obesity show GLP-1 drugs at weight-loss doses reduced absolute lean mass by an average of 1.74 kg, with semaglutide showing the biggest loss at 5.44 kg. Even so, lean mass as a proportion of total body weight improved by 1.81%, since total weight fell faster still.
- Study design
- Meta-analysis
- Journal
- Int J Obes (Lond)
- Evidence
- well supported
What it shows: Reasonably solid on the headline numbers: results pooled from seven trials covering 821 people with obesity, all tested against placebo. The trials disagreed a lot on the size of the muscle loss, and none compared the drugs against diet and exercise plans, so it cannot say how much muscle a person who trains would keep.Meta-analysis · Int J Obes (Lond)
Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs). Int J Obes (Lond) 2026Read the study →